nemolizumab

Details

Key Milestones2
Call for patient/clinician input openJanuary 15, 2025
Call for patient/clinician input closedMarch 10, 2025
Submission receivedFebruary 27, 2025
Submission acceptedMarch 13, 2025
Review initiatedMarch 17, 2025
Draft CADTH review report(s) provided to sponsor for commentJune 02, 2025
Deadline for sponsors commentsJune 11, 2025
CDA-AMC review report(s) and responses to comments provided to sponsorJuly 11, 2025
Expert committee meeting (initial)July 23, 2025
Draft recommendation issued to sponsorAugust 05, 2025
To
August 07, 2025
Draft recommendation posted for stakeholder feedbackAugust 14, 2025
End of feedback periodAugust 28, 2025

tofersen

Details

Key Milestones2
Call for patient/clinician input open15-Jan-25
Call for patient/clinician input closed10-Mar-25
Submission received27-Feb-25
Submission accepted13-Mar-25
Review initiated17-Mar-25
Draft CADTH review report(s) provided to sponsor for comment09-Jun-25
Deadline for sponsors comments18-Jun-25
CDA-AMC review report(s) and responses to comments provided to sponsor11-Jul-25
Expert committee meeting (initial)23-Jul-25
Draft recommendation issued to sponsorAugust 05, 2025
To
August 07, 2025
Draft recommendation posted for stakeholder feedback14-Aug-25
End of feedback period28-Aug-25

trabectedin

Details

Key Milestones2
Call for patient/clinician/industry input open 9-Jan-25
Call for patient/clinician/industry input closed 3-Mar-25
Review initiated11-Feb-25
Expert committee meeting (initial)17-Jul-25

cabozantinib

Details

Key Milestones2
Call for patient/clinician/industry input open 9-Jan-25
Call for patient/clinician/industry input closed 3-Mar-25
Review initiated06-Feb-25
Expert committee meeting (initial)17-Jul-25